臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

跳至:
或输入年份:

从最近的开始

由旧到新排序

显示项目 2264331-2264355 / 2310863 (共92435页)
<< < 90569 90570 90571 90572 90573 90574 90575 90576 90577 90578 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-06-10T06:10:56Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2022-06-10T06:10:56Z	First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma	Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏	2022-06-10T06:10:57Z	Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status	Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN; Yang M.-C.
臺大學術典藏	2022-06-10T06:10:57Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:10:57Z	Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma	ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:58Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:10:58Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:10:59Z	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma	Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏	2022-06-10T06:10:59Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏	2022-06-10T06:11:00Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN; Lai M.-S.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏	2022-06-10T06:11:00Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏	2022-06-10T06:11:00Z	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)	Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.
臺大學術典藏	2022-06-10T06:11:01Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; ZHONG-ZHE LIN; Lan K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2022-06-10T06:11:02Z	Young patients with colorectal cancer have increased risk of second primary cancers	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:02Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:03Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:03Z	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma	Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:04Z	Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma	Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:04Z	Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer	Chen K.-H.; Shao Y.-Y.; ZHONG-ZHE LIN; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:04Z	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption	ZHONG-ZHE LIN; Chou C.-H.; Cheng A.-L.; Liu W.-L.; Chia-Hsien Cheng J.
臺大學術典藏	2022-06-10T06:11:05Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:05Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2022-06-10T06:11:06Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2022-06-10T06:11:06Z	The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme	Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN; Cheng A.-L.; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.
臺大學術典藏	2022-06-10T06:11:06Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN

显示项目 2264331-2264355 / 2310863 (共92435页)
<< < 90569 90570 90571 90572 90573 90574 90575 90576 90577 90578 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :2826208
	造访人次 : 31904427 在线人数 : 1341 教育部委托研究计画计画执行:国立台湾大学图书馆